Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in ...

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...

Abstract #5279: Pharmacokinetics, Safety and Efficacy of Dupilumab in a Pediatric Population with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Phase 2a Trial ...

Regeneron Pharmaceuticals, Inc. REGN and its partner Sanofi SNY announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Atopic dermatitis is the most common form of eczema and estimates suggest as many as 300,000 sufferers are in need of new treatment options, the companies said in a joint statement.

Sanofi and Regeneron want to stop bullying around atopic dermatitis. So this fall, the drugmaker partners launched the “Agents of Change” AD Challenge and asked people to submit ideas.

Regeneron and Sanofi’s pitch for the moderate-to-severe atopic dermatitis market is underpinned by data from a trio of Phase III trials that were unveiled earlier this year. Those studies showed ...

Regeneron Pharmaceuticals Inc. REGN 1.43% and Sanofi SA SAN -1.34% said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in ...

Abstract #5267: Long-Term Management of Moderate-To-Severe Atopic Dermatitis (AD) with Dupilumab up to 1 Year with Concomitant Topical Corticosteroids (TCS): a Randomized, Placebo-Controlled Phase ...